*Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA †Department of Otolaryngology, University of California Davis School of Medicine, Sacramento, CA ‡Celilo Radiation Therapy, Mid-Columbia Medical Center, The Dalles, OR.
Am J Clin Oncol. 2015 Feb;38(1):47-50. doi: 10.1097/COC.0b013e3182880b7a.
Malignant pleural mesothelioma (MPM) is a fatal disease lacking standardized treatment. We describe the use of fast neutron radiation therapy in MPM patients referred to the Department of Radiation Oncology at the University of Washington Medical Center.
Retrospective chart review of MPM patients receiving neutron radiotherapy treatment from 1980 to 2012.
A total of 30 MPM patients received fast neutron radiotherapy as part of their treatment regimen. Median age at diagnosis was 59.6 years (range, 46.6 to 72.3 y). Eighteen patients received fast neutron radiotherapy as a component of trimodality treatment. Median overall survival was 20.3 months (range, 5.5 to 73.3 mo) with 1 patient censored at 34.8 months and all other patients with confirmed dates of death. One patient receiving radiotherapy alone as a palliative measure died during radiation treatment. One patient was unable to tolerate radiotherapy and stopped before completing prescribed treatment. On univariate analysis, Brigham Stage at presentation was a significant predictor of survival (P<0.01). No significant differences in survival were observed when comparing patients who received trimodality treatment compared to those who did not.
Fast neutron radiotherapy may be utilized in the management of MPM patients. However, treatment with fast neutron radiotherapy did not significantly improvement outcome, even when used in a trimodality regimen.
恶性胸膜间皮瘤（MPM）是一种致命疾病，缺乏标准化的治疗方法。我们描述了在华盛顿大学医学中心放射肿瘤科就诊的 MPM 患者中使用快中子放射治疗的情况。
回顾性分析 1980 年至 2012 年接受中子放射治疗的 MPM 患者的病历。
共有 30 名 MPM 患者接受了快中子放射治疗作为其治疗方案的一部分。诊断时的中位年龄为 59.6 岁（范围为 46.6 至 72.3 岁）。18 名患者接受了快中子放射治疗作为三联疗法的一部分。中位总生存期为 20.3 个月（范围为 5.5 至 73.3 个月），1 例患者在 34.8 个月时被删失，所有其他患者均有确认的死亡日期。1 例单独接受放射治疗作为姑息治疗的患者在放射治疗期间死亡。1 例患者因无法耐受放射治疗而在完成规定治疗前停止治疗。单因素分析显示，就诊时的布里格姆分期是生存的显著预测因素（P<0.01）。接受三联治疗的患者与未接受三联治疗的患者相比，生存无显著差异。
快中子放射治疗可用于 MPM 患者的治疗。然而，即使在三联治疗方案中使用，快中子放射治疗也不能显著改善预后。
